TRx is now developing a wholly-owned pipeline in CNS, cancer & respiratory disease.
- Emerging co-development data supports pipeline selection and development strategy
- Focus on high unmet need, clinical viability and therapeutic innovation
- Build an experienced team, progressing a series of programmes to optimal out-licensing value
Independent development of assets has commenced following closure of our first funding round. TRx is targeting a Series A fundraise during late 2022 enabling entry to clinic.